Lemonade Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Lemonade wird ein jährliches Gewinn- und Umsatzwachstum von 23.9% bzw. 20.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -32.8% betragen.
Wichtige Informationen
23.0%
Wachstumsrate der Gewinne
19.9%
EPS-Wachstumsrate
| Insurance Gewinnwachstum | 8.2% |
| Wachstumsrate der Einnahmen | 20.8% |
| Zukünftige Eigenkapitalrendite | -32.8% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 17 Jul 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Lemonade: Close To Turning Profitable, A Sour Taste On Valuation
Jul 08Lemonade, Inc.'s (NYSE:LMND) Earnings Haven't Escaped The Attention Of Investors
Jun 14
Lemonade: Tilting Consistently Toward Breakeven
May 02Lemonade: 2024 Should Be A Successful Year For This Insurer
Apr 01Lemonade: Profit Inflection Close, But Still No Juice For Bulls
Feb 28Lemonade, Inc. (NYSE:LMND) Not Lagging Industry On Growth Or Pricing
Feb 05Lemonade: Premiums Are Growing And Losses Are Slimming
Nov 28When Life Gives You Lemonade, Book Your Tax Losses
Nov 02Why Lemonade Is A Smart Long-Term Investment
Oct 19Lemonade Q2 Earnings: Analyzing The Synthetic Agents Model
Aug 15Lemonade: Ignore Outliers, Focus On The Long Term
Aug 08Lemonade: A Sweet Taste Of Upside For The Right Investor
Jul 21Lemonade Is Just Getting Started
Jun 20Lemonade: Big Strides On All Fronts
Jun 06Revenues Tell The Story For Lemonade, Inc. (NYSE:LMND)
Apr 17Lemonade GAAP EPS of -$0.93 beats by $0.28, revenue of $88.4M beats by $10.17M
Feb 22BNP Paribas Cardif and Lemonade to offer 100% online renters insurance
Feb 14Prudential And Lemonade: The End Of The Pair Trade
Jan 23Lemonade: Fairly Valued, But On The Clock
Dec 23Lemonade: Hold On For The Long Haul
Dec 12Lemonade Q3 Earnings: The Good, The Bad, But Thankfully No Ugly
Nov 10Chewy deepens pet insurance offering using Lemonade plans in new partnership
Oct 20Lemonade: A Deep Dive Into A Shallow Moat
Oct 13Lemonade: The Rebound Is Here
Sep 12Brokers Are Upgrading Their Views On Lemonade, Inc. (NYSE:LMND) With These New Forecasts
Aug 11Lemonade: Extremely Expensive Even If Path To Profitability Materializes
Aug 09Lemonade offloads Metromile's EBS platform to EIS
Aug 01Lemonade stock slips after Piper Sandler cuts to Neutral as net losses persist
Jul 18Buy Prudential And Go Drink Lemonade
Jul 03Is Lemonade A Sweet Investment Right Now?
Jun 22Lemonade: Ready For The Rebound
May 16Lemonade: When Will The Juice Run Dry?
May 09Lemonade: Just As Unappetizing This Year As Last
Apr 14Lemonade: Building A Full Insurance Flywheel, Even Though It Requires Some Trust
Mar 27Lemonade: Not An Investment For The Faint Of Heart
Mar 13Lemonade In 2022: Still A Lemon
Feb 18InsurTech Stocks: Lemonade Holding Aces Against Root
Feb 09When Life Gives You Lemonade
Jan 06Lemonade Stock: Cheaper For A Reason
Dec 28Lemonade: After Recent Crash, Buying Opportunity May Be Around The Corner
Dec 14LMND: Is It Fireworks At The Horizon Or Simply Fairyland Aflame?
Nov 03Where Will Lemonade Stock Be In 5 Years? Aiming For Auto Insurance Leadership
Oct 18Lemonade's Stock Is Still Crazy Expensive And Likely To Fall Further
Oct 12Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 842 | -119 | 42 | N/A | 3 |
| 12/31/2025 | 662 | -175 | -49 | -101 | 8 |
| 12/31/2024 | 516 | -209 | -118 | -128 | 8 |
| 3/31/2024 | 454 | -218 | -111 | -102 | N/A |
| 12/31/2023 | 430 | -237 | -128 | -119 | N/A |
| 9/30/2023 | 403 | -258 | -141 | -132 | N/A |
| 6/30/2023 | 362 | -288 | -190 | -180 | N/A |
| 3/31/2023 | 308 | -289 | -180 | -170 | N/A |
| 12/31/2022 | 257 | -298 | -173 | -163 | N/A |
| 9/30/2022 | 209 | -304 | -194 | -184 | N/A |
| 6/30/2022 | 171 | -279 | -177 | -168 | N/A |
| 3/31/2022 | 149 | -267 | -154 | -144 | N/A |
| 12/31/2021 | 128 | -241 | -154 | -145 | N/A |
| 9/30/2021 | 108 | -205 | -124 | -115 | N/A |
| 6/30/2021 | 90 | -169 | -120 | -113 | N/A |
| 3/31/2021 | 92 | -135 | -118 | -113 | N/A |
| 12/31/2020 | 94 | -122 | -96 | -92 | N/A |
| 9/30/2020 | 97 | -121 | -92 | -89 | N/A |
| 6/30/2020 | 99 | -121 | -79 | -76 | N/A |
| 3/31/2020 | 83 | -123 | -80 | -77 | N/A |
| 12/31/2019 | 67 | -108 | -81 | -78 | N/A |
| 9/30/2019 | 52 | -90 | -74 | -71 | N/A |
| 6/30/2019 | 41 | -74 | -61 | -59 | N/A |
| 3/31/2019 | 30 | -63 | -53 | -52 | N/A |
| 12/31/2018 | 23 | -53 | -41 | -41 | N/A |
| 12/31/2017 | 2 | -28 | N/A | -19 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: LMND wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: LMND wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: LMND wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: LMNDDie Einnahmen des Unternehmens (20.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: LMNDDie Einnahmen des Unternehmens (20.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: LMND wird voraussichtlich in 3 Jahren unrentabel sein.